Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism

This case demonstrates how the combination of analytical toxicology and pharmacogenetic analyses enhances a physician's ability to personalize drug therapy in patients with chronic pain syndromes.